Which of the following is a stopping criterion for NMES treatment?

Which of the following is a stopping criterion for NMES treatment?

• A. 70% strength of uninvolved side
• B. 85% strength of uninvolved side, strength plateau, or intolerance
• C. 6 weeks completed
• D. Pain level above 3/10

Answer: (B)

The stopping criteria for NMES therapy are meant to balance meaningful gains with safety and efficiency. The best practice is to discontinue or taper NMES when the target muscle has reached a level close to normal strength on the same side, when progress plateaus, or when the patient cannot tolerate the stimulation. Reaching about 85% of the strength of the uninvolved side provides a practical, objective target that indicates near-symmetric strength without pushing into overuse. If strength gains stall (a plateau), continuing NMES is unlikely to produce further meaningful improvements, signaling a good point to reassess or stop. If the patient experiences intolerance—pain, excessive fatigue, or adverse responses—the treatment must stop to protect safety. Other options miss one or more of these important safeguards: a fixed 70% threshold isn’t the standard target, relying on a set duration like six weeks ignores individual progress, and using only a pain level cutoff doesn’t account for objective progress or safety. The combination of a strength threshold, progress monitoring, and intolerance covers practical, safe stopping points.

The stopping criteria for NMES therapy are meant to balance meaningful gains with safety and efficiency. The best practice is to discontinue or taper NMES when the target muscle has reached a level close to normal strength on the same side, when progress plateaus, or when the patient cannot tolerate the stimulation.

Reaching about 85% of the strength of the uninvolved side provides a practical, objective target that indicates near-symmetric strength without pushing into overuse. If strength gains stall (a plateau), continuing NMES is unlikely to produce further meaningful improvements, signaling a good point to reassess or stop. If the patient experiences intolerance—pain, excessive fatigue, or adverse responses—the treatment must stop to protect safety.

Other options miss one or more of these important safeguards: a fixed 70% threshold isn’t the standard target, relying on a set duration like six weeks ignores individual progress, and using only a pain level cutoff doesn’t account for objective progress or safety. The combination of a strength threshold, progress monitoring, and intolerance covers practical, safe stopping points.